Historique
Rapport
WHO expert committee on drug dependence. 45th report
Auteur(s) :
OMS / WHO (Organisation mondiale de la santé / World Health Organization) ;
Forty-fifth meeting of the WHO Expert Committee on Drug Dependence (ECDD) (10-13 October 2022; WHO headquarters, Geneva, Switzerland)
Année
2023
Page(s) :
266 p.
Langue(s) :
Anglais
Éditeur(s) :
Genève : OMS / WHO
Collection :
Rapports techniques / Technical report series, 1046
ISBN :
978-92-4-006873-5
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus géographique
INTERNATIONAL
Thésaurus mots-clés
RECOMMANDATION
;
CONTROLE DES STUPEFIANTS
;
DROIT INTERNATIONAL
;
CANNABIS
;
DROGUES DE SYNTHESE
;
CATHINONES
;
CHIMIE
;
POTENTIEL ADDICTIF
;
FABRICATION
;
PHARMACOLOGIE
;
ETUDE DE CAS
;
TOXICOLOGIE
;
OPIOIDES
Autres mots-clés
Résumé :
The International Drug Control Conventions of 1961 and 1971 mandate WHO to make recommendations to the United Nations Secretary-General on the need for and level of international control of psychoactive substances according to the advice of its independent scientific advisory body, the ECDD.
At its forty-fifth meeting, the ECDD critically reviewed nine new psychoactive substances, comprising one synthetic cannabinoid receptor agonist (ADBBUTINACA), two benzodiazepines (adinazolam, bromazolam) four novel synthetic opioids (protonitazene, etazene, etonitazepyne, 2-methyl-AP-237) and two cathinones/stimulants (a-PiHP and 3-Methylmethcathinone). A critical review was undertaken of data on the use of each substance and its effects, so that the Expert Committee could determine whether the information available on these substances justified scheduling in the 1961 or 1971 Convention. In addition, the meeting pre-reviewed zopiclone, to determine whether the current information justified a critical review.
After the Forty-fifth Meeting of the ECDD, WHO endorsed and submitted the following recommendations to the United Nations Secretary-General for further consideration by the Commission on Narcotic Drugs.
At its forty-fifth meeting, the ECDD critically reviewed nine new psychoactive substances, comprising one synthetic cannabinoid receptor agonist (ADBBUTINACA), two benzodiazepines (adinazolam, bromazolam) four novel synthetic opioids (protonitazene, etazene, etonitazepyne, 2-methyl-AP-237) and two cathinones/stimulants (a-PiHP and 3-Methylmethcathinone). A critical review was undertaken of data on the use of each substance and its effects, so that the Expert Committee could determine whether the information available on these substances justified scheduling in the 1961 or 1971 Convention. In addition, the meeting pre-reviewed zopiclone, to determine whether the current information justified a critical review.
After the Forty-fifth Meeting of the ECDD, WHO endorsed and submitted the following recommendations to the United Nations Secretary-General for further consideration by the Commission on Narcotic Drugs.